Inactive Instrument
Antibe Therapeutics Inc. Stock
Stocks
ATE
CA0370255097
Biotechnology & Medical Research
OTC Markets Traded| 24-07-03 | Antibe Therapeutics : NOTICE TO CLAIMANTS OF ANTIBE THERAPEUTICS INC. (“ANTIBE”) | PU |
| 24-04-24 | Antibe Announces Appointment of Receiver | BU |
| 24-04-22 | ANTIBE PROVIDES UPDATE ON CCAA PROCEEDINGS | AQ |
| 24-04-19 | Antibe Provides Update on CCAA Proceedings | BU |
| 24-04-16 | Antibe Announces TSX Delisting Review | BU |
| Manager | Title | Age | Since |
|---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 2015-11-30 |
David Vaughan
CTO | Chief Tech/Sci/R&D Officer | 76 | - |
| Investor Relations Contact | 50 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 24-03-07 | Option | Chief Technology Officer | 16,666 | 0.0317% | ||
| 24-03-07 | Option | Chief Technology Officer | 9,000 | 0.0171% | ||
| 24-03-07 | Option | Chief Technology Officer | 16,666 | 0.0317% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +59.46% | - | - | 11.47M | |
| +0.33% | +1.37% | +64.03% | +119.11% | 55.63B | |
| +0.82% | +15.05% | +79.93% | +84.34% | 52.25B | |
| +1.36% | +0.36% | -14.06% | -14.69% | 23.07B | |
| -1.04% | +7.91% | +1.61% | +419.24% | 22.41B | |
| -0.18% | +7.20% | +32.16% | -14.07% | 17.32B | |
| -1.10% | +4.00% | +28.70% | -34.51% | 15.94B | |
| -3.35% | +8.96% | +132.20% | +290.18% | 13.47B | |
| +2.89% | +5.51% | +27.11% | +181.45% | 13.77B | |
| +1.31% | +0.53% | +28.62% | - | 12.43B | |
| Average | +0.10% | +4.78% | +42.26% | +128.88% | 25.14B | |
| Weighted average by Cap. | +0.26% | +5.13% | +48.50% | +120.17% |
Employees
11
